Next Article in Journal
Current and Prospective Protein Biomarkers of Lung Cancer
Previous Article in Journal
Role of LFA-1 and ICAM-1 in Cancer
Open AccessReview

Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology

by Paul Hofman 1,2,3
1
Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, 30 Avenue de la Voie Romaine, 06001 Nice, CEDEX 01, France
2
Côte d’Azur University, FHU OncoAge, 30 Avenue de la Voie Romaine, 06001 Nice, CEDEX 01, France
3
Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, 30 Avenue de la Voie Romaine, 06001 Nice Cedex 01, France
Academic Editor: David Wong
Cancers 2017, 9(11), 154; https://doi.org/10.3390/cancers9110154
Received: 12 October 2017 / Revised: 6 November 2017 / Accepted: 8 November 2017 / Published: 10 November 2017
The practice of liquid biopsy (LB) has revolutionized the care of patients with metastatic lung cancer. Many oncologists now use this approach in daily practice, applying precise procedures for the detection of activating or resistance mutations in EGFR. These tests are performed with plasma DNA and have been approved as companion diagnostic test for patients treated with tyrosine kinase inhibitors. ALK is another important target in lung cancer since it leads to treatment of patients who are positive for a rearrangement in ALK identified with tumor tissue. By analogy with EGFR, LB for detection of genomic alterations in ALK (rearrangements or mutations) has been rapidly adopted in the clinic. However, this promising approach has some limitations and has not yet been disseminated as much as the blood test targeting EGFR. In addition to these two therapeutic targets LB can be used for evaluation of the genomic status of other genes of interest of patients with lung cancer (ROS1, RET, NTRK MET, BRAF, HER2, etc.). LB can be performed to evaluate a specific target or for a more or less complex panel of genes. Considering the number of potential targets for clinical trials, techniques of next-generation sequencing of circulating DNA are on the rise. This review will provide an update on the contribution of LB to care of patients with metastatic lung cancer, including the present limits of this approach, and will consider certain perspectives. View Full-Text
Keywords: liquid biopsy; lung cancer; EGFR; ALK; stratified medicine liquid biopsy; lung cancer; EGFR; ALK; stratified medicine
MDPI and ACS Style

Hofman, P. Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology. Cancers 2017, 9, 154.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop